Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carlos Rubio

Showing results (101-110 of 135) with videos related to

Pageof 14
Sort By:
AIDS Reviews|August 12, 2024
HIV-1 resistance and virological failure to treatment with the integrase inhibitors bictegravir, cabotegravir, and dolutegravir: a systematic literature reviewJos柩 L Blanco-Arévalo, Miguel García-Deltoro, Miguel Torralba, et al.
Journal of Comparative Effectiveness Research|January 10, 2025
Cost-effectiveness of cetuximab combined with radiotherapy versus radiotherapy alone in locally advanced head and neck cancer in SpainRuth Álvarez Cabellos, Jon Cacicedo, Susana Redondo Capafons, et al.
Journal of Health Economics and Outcomes Research|May 27, 2022
Cost Analysis of the Use of Voriconazole, Posaconazole and Micafungin in the Primary Prophylaxis of Invasive Fungal Infections in Recipients of Allogeneic Hematopoietic Stem Cell TransplantsSantiago Grau, Carlos Solano, Carol García-Vidal, et al.
International Journal of Environmental Research and Public Health|January 6, 2019
Does Europe Need an EU Product Safety Directive for Access Scaffolding?Juan Carlos Rubio-Romero, Manuel Suárez-Cebador, María Del Carmen Pardo-Ferreira, et al.
Revista Espanola De Salud Publica|October 9, 2013
[Economic evaluation of rheumathoid arthritis monotherapy with tocilizumab and adalimumab]Federico Navarro Sarabia, Francisco J Blanco, José Ma Álvaro Gracia, et al.
Journal of Medical Economics|August 21, 2023
Cost-effectiveness of apixaban and rivaroxaban in thromboprophylaxis of cancer patients treated with chemotherapy in SpainAndrés J Muñoz, Laura Ortega, Ana Gutiérrez, et al.
Human Mutation|February 22, 2002
The A8296G mtDNA mutation associated with several mitochondrial diseases does not cause mitochondrial dysfunction in cybrid cell linesBelén Bornstein, Jose Antonio Mas, Miguel Angel Fernández-Moreno, et al.
Gastroenterologia Y Hepatologia|October 15, 2013
Pharmacoeconomic analysis of the treatment of chronic hepatitis C with peginterferon alfa-2a or peginterferon alfa-2b plus ribavirin in SpainJuan Turnes, Manuel Romero-Gómez, Ramón Planas, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|April 17, 2019
Extended-pulsed fidaxomicin versus vancomycin in patients 60 years and older with Clostridium difficile infection: cost-effectiveness analysis in SpainCarlos Rubio-Terrés, José María Aguado, Benito Almirante, et al.
Revista Espanola De Cardiologia (English Ed.)|December 16, 2014
Cost-effectiveness Analysis Comparing Apixaban and Acenocoumarol in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation in SpainGonzalo Barón Esquivias, Ginés Escolar Albaladejo, José Luis Zamorano, et al.
Pageof 14

Showing results (101-110 of 135) with videos related to

Sort By:
Pageof 14
AIDS Reviews|August 12, 2024
HIV-1 resistance and virological failure to treatment with the integrase inhibitors bictegravir, cabotegravir, and dolutegravir: a systematic literature reviewJos柩 L Blanco-Arévalo, Miguel García-Deltoro, Miguel Torralba, et al.
Journal of Comparative Effectiveness Research|January 10, 2025
Cost-effectiveness of cetuximab combined with radiotherapy versus radiotherapy alone in locally advanced head and neck cancer in SpainRuth Álvarez Cabellos, Jon Cacicedo, Susana Redondo Capafons, et al.
Journal of Health Economics and Outcomes Research|May 27, 2022
Cost Analysis of the Use of Voriconazole, Posaconazole and Micafungin in the Primary Prophylaxis of Invasive Fungal Infections in Recipients of Allogeneic Hematopoietic Stem Cell TransplantsSantiago Grau, Carlos Solano, Carol García-Vidal, et al.
International Journal of Environmental Research and Public Health|January 6, 2019
Does Europe Need an EU Product Safety Directive for Access Scaffolding?Juan Carlos Rubio-Romero, Manuel Suárez-Cebador, María Del Carmen Pardo-Ferreira, et al.
Revista Espanola De Salud Publica|October 9, 2013
[Economic evaluation of rheumathoid arthritis monotherapy with tocilizumab and adalimumab]Federico Navarro Sarabia, Francisco J Blanco, José Ma Álvaro Gracia, et al.
Journal of Medical Economics|August 21, 2023
Cost-effectiveness of apixaban and rivaroxaban in thromboprophylaxis of cancer patients treated with chemotherapy in SpainAndrés J Muñoz, Laura Ortega, Ana Gutiérrez, et al.
Human Mutation|February 22, 2002
The A8296G mtDNA mutation associated with several mitochondrial diseases does not cause mitochondrial dysfunction in cybrid cell linesBelén Bornstein, Jose Antonio Mas, Miguel Angel Fernández-Moreno, et al.
Gastroenterologia Y Hepatologia|October 15, 2013
Pharmacoeconomic analysis of the treatment of chronic hepatitis C with peginterferon alfa-2a or peginterferon alfa-2b plus ribavirin in SpainJuan Turnes, Manuel Romero-Gómez, Ramón Planas, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|April 17, 2019
Extended-pulsed fidaxomicin versus vancomycin in patients 60 years and older with Clostridium difficile infection: cost-effectiveness analysis in SpainCarlos Rubio-Terrés, José María Aguado, Benito Almirante, et al.
Revista Espanola De Cardiologia (English Ed.)|December 16, 2014
Cost-effectiveness Analysis Comparing Apixaban and Acenocoumarol in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation in SpainGonzalo Barón Esquivias, Ginés Escolar Albaladejo, José Luis Zamorano, et al.
Pageof 14